The DANPCs are transplanted to the putamen, a small structure located in the mid-brain, in a single transplantation procedure using ClearPoint MRI guidance, the SmartFlow® Cannula, and the Aspen Metered Delivery Syringe (AMDS). This surgical approach was developed by the trial’s lead neurosurgeon and renowned MRI-guided stereotactic neurosurgery pioneer
“We are thrilled to partner with
The ClearPoint Neuro Navigation System utilizes intraprocedural MR images to provide navigational instruction for the neurosurgeon, and confirmation that the desired anatomical target has been reached with submillimetric accuracy. Combined with the SmartFlow® Cannula, which is less than 2 millimeters in diameter, this allows for minimally invasive delivery of therapeutic agents in a patient’s brain.
About the ASPIRO Trial
The Autologous-derived Study of a Parkinson’s Investigational Regenerative therapy in an Open-label trial (
The primary study endpoint is safety and tolerability of ANPD001. Secondary endpoints include improvement in “on” time, when patients experience periods of symptom control, and improvements in motor symptoms and quality of life based on standard Parkinson’s disease rating scales.
About ANPD001
ANPD001 is an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD. Aspen’s personalized approach means that patients do not require immunosuppressive drugs to counteract the body’s immune response against foreign cells.
Aspen’s manufacturing process starts from a small sample of the patient’s own skin cells, followed by reprogramming to induced pluripotent stem cells (iPSCs) and then differentiation of the iPSCs into dopaminergic neuron precursor cells (DANPCs). These DANPCs are transplanted into the putamen, replacing cells that were lost or damaged due to disease. The quality of each person’s cells is assessed at every manufacturing stage using Aspen’s proprietary machine learning-based genomics tests.
About Aspen Neuroscience
Headquartered in
Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and quality control. For more information and important updates, please visit https://www.aspenneuroscience.com.
About
Forward-Looking Statements
This press release contains forward-looking statements within the context of the federal securities laws, which may include the Company’s expectations for the future performance, market, and revenue of its products and services. These forward-looking statements are based on management’s current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s products and services; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their delivery of therapies; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended
![](https://ml.globenewswire.com/media/M2QzZjc5MTktNDRmOS00OTkxLWE5YTctNGM3NzY5OTI1MjhiLTEwMzgxNDQ=/tiny/ClearPoint-Neuro-Inc-.png)
Contact: Media Contact:Jacqueline Keller , Vice President of Marketing (888) 287-9109 ext. 4 info@clearpointneuro.com Investor Relations: Danilo D’Alessandro, Chief Financial Officer (888) 287-9109 ext. 3 ir@clearpointneuro.com
2024 GlobeNewswire, Inc., source